Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) just unveiled an announcement.
Shanghai Henlius Biotech, Inc. has announced a board meeting scheduled for August 25, 2025, to review and approve the interim results for the first half of 2025 and to discuss the potential payment of an interim dividend. This meeting could influence the company’s financial strategy and shareholder returns, potentially impacting its market position and investor relations.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a company incorporated in the People’s Republic of China, operating within the biotechnology industry. The company focuses on the development and commercialization of biologic drugs, with a market emphasis on innovative therapies and biosimilars.
Average Trading Volume: 1,316,817
Technical Sentiment Signal: Buy
Current Market Cap: HK$38.04B
For a thorough assessment of 2696 stock, go to TipRanks’ Stock Analysis page.